The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors ...

Manufacturing companies are particularly attentive to drugs designated as breakthrough therapies due to the accelerated market access and higher returns on investment. Breakthrough therapy drugs often ...

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining ...

Jazz Pharmaceuticals plc is a Buy with its robust portfolio, potential FDA approvals, and innovative oncology treatments.

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The Business Research Company's Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge It will grow to $50.99 billion in 2029 at a compound annual ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Dizal will market sunvozertinib in the US under the Zegfrovy brand name, entering a market for EGFR inhibitors currently ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...